TY - JOUR
T1 - Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients
T2 - A literature review and a case series of 17 patients from 3 studies
AU - Ruan, Can Jun
AU - Olmos, Ismael
AU - Ricciardi, Carina
AU - Schoretsanitis, Georgios
AU - Vincent, Philippe D.
AU - Anıl Yağcıoğlu, A. Elif
AU - Eap, Chin B.
AU - Baptista, Trino
AU - Clark, Scott R.
AU - Fernandez-Egea, Emilio
AU - Kim, Se Hyun
AU - Lane, Hsien Yuan
AU - Leung, Jonathan
AU - Maroñas Amigo, Olalla
AU - Motuca, Mariano
AU - Every-Palmer, Susanna
AU - Procyshyn, Ric M.
AU - Rohde, Christopher
AU - Suhas, Satish
AU - Schulte, Peter F.J.
AU - Spina, Edoardo
AU - Takeuchi, Hiroyoshi
AU - Verdoux, Hélène
AU - Correll, Christoph U.
AU - Molden, Espen
AU - De Las Cuevas, Carlos
AU - de Leon, Jose
N1 - Publisher Copyright:
© 2023
PY - 2024/6
Y1 - 2024/6
N2 - Background: Up to 1/2 of outpatients prescribed clozapine may be partially/fully non-adherent, based on therapeutic drug monitoring (TDM). Three indices for measuring partial/full non-adherence are proposed a: 1) clozapine concentration/dose (C/D) ratio which drops to half or more of what is expected in the patient; 2) clozapine/norclozapine ratio that becomes inverted; and 3) clozapine concentration that becomes non-detectable. Methods: These 3 proposed indices are based on a literature review and 17 cases of possible non-adherence from 3 samples: 1) an inpatient study in a Chinese hospital, 2) an inpatient randomized clinical trial in a United States hospital, and 3) and a Uruguayan outpatient study. Results: The first index of non-adherence is a clozapine C/D ratio which is less than half the ratio corresponding to the patient's specific ancestry group and sex-smoking subgroup. Knowing the minimum therapeutic dose of the patient based on repeated TDM makes it much easier to establish non-adherence. The second index is inverted clozapine/norclozapine ratios in the absence of alternative explanations. The third index is undetectable concentrations. By using half-lives, the chronology of the 3 indices of non-adherence was modeled in two patients: 1) the clozapine C/D ratio dropped to ≥1/2 of what is expected from the patient (around day 2); 2) the clozapine/norclozapine ratio became inverted (around day 3); and 3) the clozapine concentration became undetectable by the laboratory (around days 9–11). Conclusion: Prospective studies should further explore these proposed clozapine indices in average patients, poor metabolizers (3 presented) and ultrarapid metabolizers (2 presented).
AB - Background: Up to 1/2 of outpatients prescribed clozapine may be partially/fully non-adherent, based on therapeutic drug monitoring (TDM). Three indices for measuring partial/full non-adherence are proposed a: 1) clozapine concentration/dose (C/D) ratio which drops to half or more of what is expected in the patient; 2) clozapine/norclozapine ratio that becomes inverted; and 3) clozapine concentration that becomes non-detectable. Methods: These 3 proposed indices are based on a literature review and 17 cases of possible non-adherence from 3 samples: 1) an inpatient study in a Chinese hospital, 2) an inpatient randomized clinical trial in a United States hospital, and 3) and a Uruguayan outpatient study. Results: The first index of non-adherence is a clozapine C/D ratio which is less than half the ratio corresponding to the patient's specific ancestry group and sex-smoking subgroup. Knowing the minimum therapeutic dose of the patient based on repeated TDM makes it much easier to establish non-adherence. The second index is inverted clozapine/norclozapine ratios in the absence of alternative explanations. The third index is undetectable concentrations. By using half-lives, the chronology of the 3 indices of non-adherence was modeled in two patients: 1) the clozapine C/D ratio dropped to ≥1/2 of what is expected from the patient (around day 2); 2) the clozapine/norclozapine ratio became inverted (around day 3); and 3) the clozapine concentration became undetectable by the laboratory (around days 9–11). Conclusion: Prospective studies should further explore these proposed clozapine indices in average patients, poor metabolizers (3 presented) and ultrarapid metabolizers (2 presented).
KW - Clozapine/blood
KW - Clozapine/metabolism
KW - Clozapine/therapeutic use
KW - Drug interaction
KW - Medication adherence
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85165655674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165655674&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2023.07.002
DO - 10.1016/j.schres.2023.07.002
M3 - Article
C2 - 37487869
AN - SCOPUS:85165655674
SN - 0920-9964
VL - 268
SP - 293
EP - 301
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -